TELA Bio®, Inc. Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffolds
January 24, 2019 at 08:30 am
Share
TELA Bio®, Inc. announced the first patient has been treated with OviTex RBSs in Europe. The complex abdominal wall repair was performed by Alastair Windsor, M.D., FRCS, at University College London Hospital in London, England. TELA Bio's partner Aroa Biosurgery, a soft-tissue repair company based in New Zealand that develops and manufactures medical products to improve healing, was granted EC Certification (CE Mark) for OviTex RBSs in the European Union (EU). The distinct class of surgical mesh integrates both biologic and synthetic materials to maintain flexibility without compromising on strength.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.